ClinicalTrials.gov: chronic kidney diseases | Last update posted in the last 7 days

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
1	NCT04411758	Propolis for Patients With Chronic Kidney Disease. Study Documents:	Title Acronym: Other Ids: Denise Mafra8	Recruiting	• Chronic Kidney Diseases • Inflammation	Dietary Supplement: Propolis 4 capsules of 500mg/day containing concentrated and standardized dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: In this clinical trial, participants with CKD undergoing hemodialysis or peritoneal dialysis will be instructed to use 4 capsules of 500mg/day containing concentrated and standardized dry EPP-AF® green propolis extract for 2 months or placebo (4 capsules of 500mg/day of magnesium stearate, silicon dioxide and microcrystalline cellulose) for two months, and then the groups will be crossed and will receive the same amount of propolis as the first group. Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Health Services Research Primary Outcome Measures: • Change in cytokines plasma levels measured by ELISA after supplementation with propolis. [Time Frame: 4 months] • Change the expression of transcription factors (Nrf2 and NF-kB), antioxidant enzymes (NQO1, HO-1), NLRP3 receptor, PPAR- [Time Frame: 4 months] • Change the profile of the intestinal microbiota of stool samples [Time Frame: 4 months] Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 60 Original Estimated Enrollment: *Same as current* Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: January 12, 2021 Primary Completion: May 29, 2023 (Final data collection date for primary outcome measure) Study Completion: June 20, 2023 First Posted: June 2, 2020 Results First Posted: Last Update Posted: September 19, 2022
2	NCT01652872	Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: 20110226	Completed	Anemia in Chronic Kidney Disease Patients Not on Dialysis	• Biological: Darbepoetin alfa Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period. Other Name: Aranesp • Other: Placebo Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Primary Outcome Measures: Receipt of 1 or more RBC transfusion [Time Frame: Approximately 2 years] Secondary Outcome Measures: • Total number of units of red blood cells (RBC) transfused. Time to first red blood cell transfusion. [Time Frame: Approximately 2 years] • Average achieved hemoglobin (Hb) concentration while receiving investigational product. [Time Frame: Up to 2 years] • Cumulative dose of darbepoetin alfa [Time Frame: Up to 2 years] • Time to first RBC transfusion [Time Frame: From randomization to the first RBC transfusion]	Actual Enrollment: 756 Estimated Enrollment: Original Estimated Enrollment: 750 Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: July 30, 2012 Primary Completion: October 19, 2017 (Final data collection date for primary outcome measure) Study Completion: October 19, 2017 First Posted: November 8, 2018 Results First Posted: November 8, 2018 Last Update Posted: September 21, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
3	NCT04413266	Effects of Curcumin Supplementation in Patients With Chronic Kidney Disease on Peritoneal Dialysis Study Documents:	Title Acronym: Other Ids: Denise Mafra7	Recruiting	• Chronic Kidney Diseases • Peritoneal Dialysis • Hemodialysis	Dietary Supplement: Curcumin supplementation The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks Other Names: • Dietary Supplement • Placebo	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Health Services Research Primary Outcome Measures: • Antioxidants and anti-inflammatory biomarkers [Time Frame: 4 weeks] Get blood samples to evaluate the supplementation effects in antioxidants biomarkers- nuclear receptor factor 2 (Nrf2), glutathioneperoxidase (GPx), heme oxygenase-1 (HO-1), NQO1 • Inflammatory biomarkers [Time Frame: 4 weeks] Get blood samples to evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappa B (NFkB), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), PCR, IL-1B, IL-18, TBARS, Inflammassome Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 30 Original Estimated Enrollment: *Same as current* Age: 18 Years to 60 Years (Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: October 10, 2020 Primary Completion: June 2023 (Final data collection date for primary outcome measure) Study Completion: June 2023 First Posted: June 2, 2020 Results First Posted: Last Update Posted: September 16, 2022
4	NCT05342623	A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus and Not on Dialysis Study Documents:	Title Acronym: Other Ids: CR845-310301	Recruiting	• Chronic Kidney Diseases • Pruritus	• Drug: Difelikefalin 1 mg Oral Tablet Difelikefalin 1 mg medication taken orally 1 time/day Other Name: CR845 • Drug: Placebo Oral Tablet Placebo tablet taken orally 1 time/day	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomized, double-blind, placebo controlled study Masking: Double (Participant, Investigator) Masking Description: Difelikefalin and placebo will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance. Difelikefalin tablets will be provided at doses of 1 mg. Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 400 Original Estimated Enrollment: *Same as current* Age: 18 Years to 85 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: May 17, 2022 Primary Completion: July 2024 (Final data collection date for primary outcome measure) Study Completion: October 2024 First Posted: April 22, 2022 Results First Posted: Last Update Posted: September 19, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
5	NCT04115345	A Study of a Renal Autologous Cell Therapy (REACT®) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Study Documents:	Title Acronym: Other Ids: REGEN-004	Recruiting	• Chronic Kidney Disease • Congenital Anomalies of Kidney and Urinary Tract	Biological: Renal Autologous Cell Therapy (REACT®) Autologous selected renal cells (SRC)	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Open-label Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: Assess change in eGFR and observe incidence of renal-specific procedure and/or product related adverse events (AEs) through 24 months following two Renal Autologous Cell Therapy (REACT) injections [Safety]. [Time Frame: 12 months following last REACT injection] The primary objective is to assess the safety and optimal delivery of Renal Autologous Cell Therapy (REACT) injected at one site in a recipient kidney as measured by procedure- and/or product related adverse events (AEs) through 12 months post-treatment. Secondary Outcome Measures: Number of subjects with renal-specific adverse events over a 24-month period following injection of Renal Autologous Cell Therapy (REACT). [Time Frame: 24 months following last REACT injection] The number of subjects with renal-specific adverse events over a 24-month period following injection of Renal Autologous Cell Therapy (REACT) will be observed utilizing renal-specific laboratory assessments.The secondary objective will compare the results of laboratory tests from baseline through 12 months following REACT injection, followed by an additional observational period of 18 months for a total of 24 months of observation. Each subject's baseline rate of CKD disease progression serves as his/her own "control" to monitor for changes in renal insufficiency over time.	Actual Enrollment: Estimated Enrollment: 15 Original Estimated Enrollment: *Same as current* Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: CTI Clinical Trial and Consulting Services	Study Start: August 13, 2019 Primary Completion: March 31, 2023 (Final data collection date for primary outcome measure) Study Completion: May 30, 2023 First Posted: October 4, 2019 Results First Posted: Last Update Posted: September 16, 2022
6	NCT04911491	Inspiratory Muscle Strength Training in Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: 21-3000 R01DK130255 (U.S. NIH Grant/Contract)	Recruiting	• Chronic Kidney Diseases • Hypertension • Aging • Blood Pressure	• Device: IMST Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device. • Device: Sham Training Repeated inhalations against a low resistance will be performed using a handheld device.	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 108 Original Estimated Enrollment: *Same as current* Age: 50 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: • University of Colorado, Boulder • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Study Start: March 1, 2022 Primary Completion: July 1, 2026 (Final data collection date for primary outcome measure) Study Completion: July 1, 2026 First Posted: June 3, 2021 Results First Posted: Last Update Posted: September 21, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
7	NCT03299816	Five, Plus Nuts and Beans for Kidneys Study Documents:	Title Acronym: Other Ids: IRB00122943 1U01MD010550-01 (U.S. NIH Grant/Contract)	Completed	• Chronic Kidney Disease • Hypertension	• Behavioral: Coaching DASH group (C-DASH) Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance. Other Name: Coaching DASH diet advice group (C-DASH) • Behavioral: Self-Shopping DASH group (S-DASH) Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases. Other Name: Self-Shopping DASH diet advice Group (S-DASH)	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Single center, randomized controlled trial with two parallel arms. Masking: Single (Outcomes Assessor) Primary Purpose: Treatment Primary Outcome Measures: • Change in Albuminuria from Baseline to 1 month [Time Frame: Baseline, 1 month] Urine samples will be collected for ACR (albumin-to-creatinine ratio). Albuminuria is defined as an ACR 30 mg/g. • Change in Albuminuria from Baseline to 4 months [Time Frame: Baseline, 4 months] Urine samples will be collected for ACR (albumin-to-creatinine ratio). Albuminuria is defined as an ACR 30 mg/g. • Change in Albuminuria from Baseline to end of study [Time Frame: Baseline, end of study (approximately 12 months)] Urine samples will be collected for ACR (albumin-to-creatinine ratio). Albuminuria is defined as an ACR 30 mg/g. Secondary Outcome Measures: • Change in Systolic Blood Pressure [Time Frame: Baseline, 1 month] Daytime systolic blood pressure monitoring will be determined using OMRON 907-xl • Change in Systolic Blood Pressure [Time Frame: Baseline,4 months] Daytime systolic blood pressure monitoring will be determined using OMRON 907-xl • Change in Systolic Blood Pressure [Time Frame: Baseline, end of study (approximately 12 months)] Daytime systolic blood pressure monitoring will be determined using OMRON 907-xl	Actual Enrollment: 142 Estimated Enrollment: Original Estimated Enrollment: 150 Age: 21 Years to 100 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)	Study Start: February 22, 2018 Primary Completion: November 22, 2021 (Final data collection date for primary outcome measure) Study Completion: December 8, 2021 First Posted: October 3, 2017 Results First Posted: Last Update Posted: September 15, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
8	NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Study Documents:	Title Acronym: Other Ids: 17217 I8F-MC-GPIG (Other Identifier: Eli Lilly and Company) 2021-005273-47 (EudraCT Number)	Not yet recruiting	• Overweight • Obesity • Chronic Kidney Disease • Type 2 Diabetes • T2D	• Drug: Tirzepatide Administered SC • Drug: Placebo Administered SC	Study Type: Interventional Phase: Phase 2 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 140 Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: October 14, 2022 Primary Completion: October 10, 2025 (Final data collection date for primary outcome measure) Study Completion: November 7, 2025 First Posted: September 13, 2022 Results First Posted: Last Update Posted: September 21, 2022
9	NCT05543291	Multi-omics Analysis of Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: SHYS-IEC-5.0/22K162/P01	Recruiting	Potential Mechanisms Underlying the Microbiota-Gut-Kidney Axis in CKD	Behavioral: renal function levels of eGFR	Study Type: Observational Phase: Study Design: Observational Model: Cohort Time Perspective: Cross-Sectional Primary Outcome Measures: *Same as current* Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 150 Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: January 1, 2022 Primary Completion: December 31, 2024 (Final data collection date for primary outcome measure) Study Completion: December 31, 2024 First Posted: September 16, 2022 Results First Posted: Last Update Posted: September 16, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
10	NCT05182840	A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: 1378.5 2021-001434-19 (EudraCT Number) 1378-0005 (Other Identifier: Boehringer Ingelheim)	Recruiting	Kidney Disease, Chronic	• Drug: BI 690517 BI 690517 • Drug: Placebo to BI 690517 Placebo to BI 690517 • Drug: Empagliflozin Empagliflozin • Drug: Placebo to empagliflozin Placebo to empagliflozin	Study Type: Interventional Phase: Phase 2 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 552 Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: January 11, 2022 Primary Completion: June 6, 2023 (Final data collection date for primary outcome measure) Study Completion: July 4, 2023 First Posted: January 10, 2022 Results First Posted: Last Update Posted: September 21, 2022
11	NCT05183737	Effects of Microencapsulated Propolis and Turmeric in Patients With Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: DeniseMafra13	Active, not recruiting	• Chronic Kidney Diseases • Inflammation	Dietary Supplement: Microcapsules with turmeric and propolis Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: The study is a longitudinal randomized, double-blind, placebo-controlled clinical trial with patients with CKD undergoing hemodialysis. Patients will be randomized and divided into two groups: intervention group, which will receive microcapsules containing 250mg of propolis and 250mg of turmeric, twice a day, for 12 weeks, and placebo group, which will receive for the same amount of capsules containing arabic gum and cornstarch. Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Health Services Research Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 34 Original Estimated Enrollment: *Same as current* Age: 18 Years to 60 Years (Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: March 7, 2022 Primary Completion: December 2022 (Final data collection date for primary outcome measure) Study Completion: December 2022 First Posted: January 11, 2022 Results First Posted: Last Update Posted: September 19, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
12	NCT05544513	Oral Iron Supplementation for Patients With Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: DeniseMafra14	Active, not recruiting	• Chronic Renal Disease • Iron-Deficiency Anemia • Anemia of Chronic Kidney Disease • Dysbiosis	Drug: Ferrous sulfate Ferrous sulfate supplementation	Study Type: Interventional Phase: Phase 2 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: *Same as current* Estimated Enrollment: Original Estimated Enrollment: Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: August 1, 2022 Primary Completion: December 29, 2023 (Final data collection date for primary outcome measure) Study Completion: December 30, 2026 First Posted: September 16, 2022 Results First Posted: Last Update Posted: September 16, 2022
13	NCT05543928	Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism Study Documents:	Title Acronym: Other Ids: CTAP101-CL-3007	Not yet recruiting	• Chronic Kidney Disease stage3 • Chronic Kidney Disease stage4 • Vitamin d Deficiency • Secondary Hyperparathyroidism	• Drug: CTAP101 CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL. • Drug: Placebo Placebo	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: Randomized Intervention Model: Sequential Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 108 Original Estimated Enrollment: *Same as current* Age: 8 Years to 17 Years (Child) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: October 2022 Primary Completion: July 2025 (Final data collection date for primary outcome measure) Study Completion: July 2025 First Posted: September 16, 2022 Results First Posted: Last Update Posted: September 16, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
14	NCT05546099	Patient-driven Management of BP in CKD Study Documents:	Title Acronym: Other Ids: IIR 21-255	Not yet recruiting	Chronic Kidney Disease	• Behavioral: Self-management of BP medications Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist. • Behavioral: Self-monitoring of home BP Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Patients will monitor home BP and adjust meds based on a protocol and under the guidance of a clinical pharmacist. Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 160 Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: November 1, 2022 Primary Completion: September 30, 2026 (Final data collection date for primary outcome measure) Study Completion: November 20, 2026 First Posted: September 19, 2022 Results First Posted: Last Update Posted: September 19, 2022
15	NCT01156428	Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease Study Documents:	Title Acronym: Other Ids: 0908010598	Completed	• Proteinuria • Kidney Injury • Chronic Kidney Disease	Not Provided	Study Type: Observational Phase: Study Design: Observational Model: Case-Control Time Perspective: Prospective Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: 119 Estimated Enrollment: Original Estimated Enrollment: 80 Age: 18 Years to 90 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Janssen Research & Development, LLC	Study Start: July 2010 Primary Completion: November 2016 (Final data collection date for primary outcome measure) Study Completion: November 2016 First Posted: July 2, 2010 Results First Posted: Last Update Posted: September 19, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
16	NCT05094934	A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function Study Documents:	Title Acronym: Other Ids: NN6435-4749 U1111-1264-2693 (Other Identifier: World Health Organization (WHO)) 2021-000462-16 (EudraCT Number)	Terminated	Chronic Kidney Disease	Drug: NNC0385-0434 A 100 mg All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: • Cmax,0434,Day10: the maximum plasma concentration of NNC0385-0434 after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to post treatment follow-up (Day 65)] nmol/L • tmax,0434,Day10: time from last dose administration to maximum plasma concentration of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to post treatment follow-up (Day 65)] h • t½,0434,Day10; the terminal half-life of NNC0385-0434 after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to post treatment follow-up (Day 65)] h • CLR,0434,Day10; the renal clearance of NNC0385-0434 after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to 48 hours post treatment (Day 12)] mL/h • CL/F0434,Day10; the apparent clearance of NNC0385-0434 after last dose of oral NNC0385-0434 [Time Frame: From last dose (day 10) to post treatment follow-up (day 65)] mL/h • Vz/F0434,Day10; the apparent volume of distribution of NNC0385-0434 in the terminal phase [Time Frame: From last dose (Day 10) to post treatment follow-up (Day 65)] L • AUC0-24h,SNAC,Day10: the area under the SNAC plasma concentration-time curve from time 0 to 24 hours after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to 24 hours post treatment (Day 11)] h*nmol/L • Cmax,SNAC,Day10; the maximum plasma concentration of SNAC after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to 24 hours post treatment (Day 11)] nmol/L • Cmin,SNAC,Day10; the minimum plasma concentration of SNAC before last dose of oral NNC0385-0434 [Time Frame: Pre-dose (Day 10)] nmol/L • tmax,SNAC,Day10; the time to maximum observed plasma concentration of SNAC after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to 24 hours post treatment (Day 11)] hours • t½,SNAC,Day10; the terminal half-life of SNAC after last dose of oral NNC0385-0434 [Time Frame: From last dose (Day 10) to 24 hours post treatment (Day 11)]	Actual Enrollment: 60 Estimated Enrollment: Original Estimated Enrollment: *Same as current* Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: November 8, 2021 Primary Completion: August 29, 2022 (Final data collection date for primary outcome measure) Study Completion: August 29, 2022 First Posted: October 26, 2021 Results First Posted: Last Update Posted: September 21, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
17	NCT05465317	Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease Study Documents:	Title Acronym: Other Ids: 1245-0228	Active, not recruiting	Diabetes Mellitus, Type 2	• Drug: Empagliflozin Empagliflozin • Drug: Dipeptidyl Peptidate-4 inhibitors Dipeptidyl Peptidate-4 inhibitors • Drug: Sodium glucose co-transporter-2 inhibitors Sodium glucose co-transporter-2 inhibitors • Drug: Glucagon-like Peptide-1 Receptor Agonists Glucagon-like Peptide-1 Receptor Agonists	Study Type: Observational Phase: Study Design: Observational Model: Cohort Time Perspective: Retrospective Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: 30400 Estimated Enrollment: Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: August 8, 2022 Primary Completion: September 30, 2022 (Final data collection date for primary outcome measure) Study Completion: September 30, 2022 First Posted: July 19, 2022 Results First Posted: Last Update Posted: September 21, 2022
18	NCT05142501	Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy Study Documents:	Title Acronym: Other Ids: HD-COVID-IR-EU	Terminated	• Chronic Kidney Diseases • COVID-19 • Hemodialysis	Other: Blood samples Four consecutive blood sampling throughout the overall follow-up period of 12 months.	Study Type: Observational Phase: Study Design: Observational Model: Other Time Perspective: Prospective Primary Outcome Measures: Humoral immune response [Time Frame: 12 months after start of study] The humoral immune response will be assessed at four different timepoints (Sample 1: prior to the third vaccine dose; sample 2: 1 months after the third vaccine dose; sample 3: 6 months after the third vaccine dose; sample 4: 12 months after the third vaccine dose or max. 4 weeks prior to the fourth vaccine dose, whichever comes first) through the measurement of the titers of Bioplex IgG antibody panel in study participant's blood samples. Secondary Outcome Measures: Not Provided	Actual Enrollment: 23 Estimated Enrollment: Original Estimated Enrollment: 340 Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: April 25, 2022 Primary Completion: September 2, 2022 (Final data collection date for primary outcome measure) Study Completion: September 2, 2022 First Posted: December 2, 2021 Results First Posted: Last Update Posted: September 15, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
19	NCT05497700	Comparative Efficacy of Ephedrine Versus Norepinephrine to Correct Anesthesia Induction Related Hypotension Study Documents:	Title Acronym: Other Ids: VASO_IRC	Recruiting	Hypotension on Induction	• Drug: Ephedrine Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg • Drug: Norepinephrine Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Drug will be prepared by an anesthesia nurse not involved in the care of the patient and labeled as "VASO-IRC-inclusion number". Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 60 Original Estimated Enrollment: *Same as current* Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: September 15, 2022 Primary Completion: September 30, 2023 (Final data collection date for primary outcome measure) Study Completion: October 30, 2023 First Posted: August 11, 2022 Results First Posted: Last Update Posted: September 16, 2022
20	NCT02683889	Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation Study Documents:	Title Acronym: Other Ids: 17-2336	Recruiting	FSGS	Drug: Acthar patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Prevention Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 20 Original Estimated Enrollment: *Same as current* Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	Study Sponsors: Georgetown University Collaborators: Not Provided	Study Start: February 1, 2019 Primary Completion: December 2023 (Final data collection date for primary outcome measure) Study Completion: December 2023 First Posted: February 17, 2016 Results First Posted: Last Update Posted: September 16, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
21	NCT02579096	CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat Study Documents:	Title Acronym: Other Ids: 594	Completed	• Gout • Chronic Kidney Diseases	• Drug: allopurinol capsule, 100-800 mg by mouth once daily Patients will be up-titrated up to the dose required to reach target uric acid levels. Other Name: Zyloprim; CAS: 315-30-0 • Drug: febuxostat tablet 40-120 mg by mouth once daily Patients will be up-titrated to the dose required to reach target uric acid levels. Other Name: Uloric; CAS: 144060-53-7; NDCs: 64764-677-11, 64764-677-13, 64764-677-19, 64764-677-30, 64764-918-11, 64764-918-18, 64764-918-30, 64764-918-90 • Drug: Placebo, vehicle control (febuxostat-shaped) Placebo tablets resembling febuxostat will be given with allopurinol. • Drug: Placebo, vehicle control (allopurinol-shaped) Placebo capsules resembling allopurinol will be given with febuxostat.	Study Type: Interventional Phase: Phase 4 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Primary Outcome Measures: Proportion of participants who have at least one gout flare in the allopurinol group compared to the febuxostat group [Time Frame: Phase III of the study (months 12-18 of study duration)] Proportion of participants who have at least one gout flare in the allopurinol group compared to the febuxostat group Secondary Outcome Measures: Not Provided	Actual Enrollment: 950 Estimated Enrollment: Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: March 6, 2017 Primary Completion: February 1, 2021 (Final data collection date for primary outcome measure) Study Completion: April 15, 2021 First Posted: January 11, 2022 Results First Posted: January 11, 2022 Last Update Posted: September 19, 2022
22	NCT05136664	Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects Study Documents:	Title Acronym: Other Ids: PAT-CHINA-303 CTR20212173 (Registry Identifier: Center for Drug Evaluation (CDE), NMPA)	Recruiting	• Hyperkalemia • Renal Insufficiency, Chronic	• Drug: Patiromer Powder for Oral Suspension (Part A) Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels. The content of each packet should be mixed with water, apple or cranberry juice before administration. • Drug: Placebo (Part B) Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice. • Drug: Patiromer Powder for Orals Suspension (Part B) Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels. The content of each packet should be mixed with water, apple or cranberry juice before administration.	Study Type: Interventional Phase: Phase 3 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: 2-part, single-blind, randomised withdrawal, placebo-controlled (Part B), parallel group study that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part B). Masking: Single (Participant) Primary Purpose: Treatment Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 200 Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Tigermed Consulting Co., Ltd	Study Start: February 10, 2022 Primary Completion: March 2024 (Final data collection date for primary outcome measure) Study Completion: March 2024 First Posted: November 29, 2021 Results First Posted: Last Update Posted: September 16, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
23	NCT05542927	Incidence of Acute Kidney Injury and Mortality in Critically Ill Patients: Urinary Chloride as a Prognostic Marker Study Documents:	Title Acronym: Other Ids: 541/2022	Recruiting	Acute Kidney Injury	Diagnostic Test: urine chloride Serum chloride, urinary chloride & serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride & urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI & mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours	Study Type: Observational [Patient Registry] Phase: Study Design: Observational Model: Cohort Time Perspective: Prospective Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 90 Original Estimated Enrollment: *Same as current* Age: 21 Years to 90 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: September 1, 2022 Primary Completion: February 28, 2023 (Final data collection date for primary outcome measure) Study Completion: March 30, 2023 First Posted: September 16, 2022 Results First Posted: Last Update Posted: September 16, 2022
24	NCT05546086	BeijngFH Health Cohort Study Study Documents:	Title Acronym: Other Ids: CFH2022-1-2021	Recruiting	Non-Alcoholic Fatty Liver Disease	Not Provided	Study Type: Observational Phase: Study Design: Observational Model: Cohort Time Perspective: Prospective Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 8103 Original Estimated Enrollment: *Same as current* Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Chinese Academy of Medical Sciences	Study Start: April 18, 2022 Primary Completion: April 18, 2032 (Final data collection date for primary outcome measure) Study Completion: April 18, 2032 First Posted: September 19, 2022 Results First Posted: Last Update Posted: September 21, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
25	NCT05545501	Ketone Ester and Acute Salt (KEAS) in Young Adults Study Documents:	Title Acronym: Other Ids: AU IRB #22-025	Not yet recruiting	• Salt; Excess • Hypertension	• Dietary Supplement: No Salt, No -OHB Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a -OHB-free, taste and viscosity-matched, beverage produced by KetoneAid. • Dietary Supplement: High Salt, No -OHB Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a -OHB-free, taste and viscosity-matched, beverage produced by KetoneAid. • Dietary Supplement: High Salt, High -OHB Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the -OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams -OHB) of the ketone beverage three times a day (total 36 grams -OHB).	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: Placebo-controlled, double-blinded, randomized Masking: Double (Participant, Investigator) Masking Description: Participants will be randomized to a condition order. A single lab member, not involved in data collection or analysis, will know condition order and contents and distribute them to participants. Primary Purpose: Basic Science Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: Estimated Enrollment: 35 Original Estimated Enrollment: *Same as current* Age: 18 Years to 39 Years (Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: • University of Utah • University of Missouri-Columbia	Study Start: October 1, 2022 Primary Completion: September 30, 2025 (Final data collection date for primary outcome measure) Study Completion: September 30, 2026 First Posted: September 19, 2022 Results First Posted: Last Update Posted: September 19, 2022
26	NCT04776980	Multimodality MRI and Liquid Biopsy in GBM Study Documents:	Title Acronym: Other Ids: 843601	Withdrawn	• Glioblastoma Multiforme • Brain Tumor, Adult: Glioblastoma • Brain Tumor, Recurrent • Brain Tumor, Primary	Diagnostic Test: Post Feraheme Infusion MRI All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.	Study Type: Interventional Phase: Early Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic Primary Outcome Measures: *Same as current* Secondary Outcome Measures: *Same as current*	Actual Enrollment: 0 Estimated Enrollment: Original Estimated Enrollment: 30 Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: University of Pennsylvania Collaborators: Not Provided	Study Start: June 2022 Primary Completion: June 2022 (Final data collection date for primary outcome measure) Study Completion: June 22, 2022 First Posted: March 2, 2021 Results First Posted: Last Update Posted: September 16, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
27	NCT02055209	Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST) Study Documents:	Title Acronym: Other Ids: 140048 14-HG-0048	Recruiting	Hypertension	Not Provided	Study Type: Observational Phase: Study Design: Observational Model: Case-Control Time Perspective: Cross-Sectional Primary Outcome Measures: To develop a novel genomic science resource for defining the functional significance and human biology consequences of ancestry-related genomic variation in AA. [Time Frame: 5 years] Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 2019 Original Estimated Enrollment: 1800 Age: 21 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: July 23, 2014 Primary Completion: July 1, 2030 (Final data collection date for primary outcome measure) Study Completion: July 1, 2030 First Posted: February 5, 2014 Results First Posted: Last Update Posted: September 16, 2022
28	NCT04603560	Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension Study Documents:	Title Acronym: Other Ids: 2020P002897	Active, not recruiting	Hypertension	• Behavioral: Audit and Feedback A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers. • Behavioral: Pharmacist E-Detailing A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Investigator, Outcomes Assessor) Primary Purpose: Health Services Research Primary Outcome Measures: Change in hypertension medication prescribing using EHR data [Time Frame: Up to 3 months] The primary outcome will be whether physicians intensified treatment at the visit targeted by the intervention. Intensification of treatment will include an increase in dose of an existing antihypertensive medication, adding an additional medication, or rotation of one medication to another that is stronger or more appropriate for the patient (e.g. changing hydrochlorothiazide to furosemide for a patient with chronic kidney disease). These will be measured using prescribing information from the EHR on the day of the patient's visit. Secondary Outcome Measures: Change in systolic blood pressure using EHR data [Time Frame: Up to 6 months] The secondary outcome will be the change in systolic blood pressure over 6-months of follow-up in each intervention arm compared to control. The initial value will be the systolic blood pressure at the time of the visit targeted by the intervention. The follow-up blood pressure will be the last blood pressure available in the EHR within 6 months after the visit targeted by the intervention.	Actual Enrollment: 505 Estimated Enrollment: Original Estimated Enrollment: 45 Age: 18 Years to 79 Years (Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: October 26, 2021 Primary Completion: August 8, 2022 (Final data collection date for primary outcome measure) Study Completion: May 31, 2023 First Posted: October 27, 2020 Results First Posted: Last Update Posted: September 19, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
29	NCT05398783	A Natural History Study of Metabolic Sizing in Health and Disease Study Documents:	Title Acronym: Other Ids: 10000617 000617-DK	Not yet recruiting	• Metabolic Disorders • Cancer • Chronic Kidney Disease • Diabetes • Normal Physiology	Not Provided	Study Type: Observational Phase: Study Design: Observational Model: Case-Control Time Perspective: Prospective Primary Outcome Measures: *Same as current* Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 2000 Original Estimated Enrollment: *Same as current* Age: 10 Years and older (Child, Adult, Older Adult) Sex: All	Study Sponsors: *Same as current* Collaborators: Not Provided	Study Start: September 26, 2022 Primary Completion: July 1, 2031 (Final data collection date for primary outcome measure) Study Completion: July 1, 2031 First Posted: June 1, 2022 Results First Posted: Last Update Posted: September 21, 2022